This study indicated that positive CXCR4 expression in lung cancer tissue did not significantly impact survival prognosis, highlighting the complexities of utilizing chemokines as standalone therapies in clinical settings despite promising preclinical results in cancer research. This evidence concerns the gene CXCR4 and lung carcinoma.